Number of treatment-related adverse events with incidence ≥10% or grade ≥3
| All grades | Grade ≥3# | ||||
| CPE | E monotherapy | p-value | CPE | E | |
| Abdominal pain | 1 | 1 | 0 | 0 | |
| Alopecia | 2 | 0 | 0.48 | 0 | 0 |
| Anaemia | 1 | 0 | 0 | 0 | |
| Anorexia | 6 | 0 | 0.01 | 1 | 0 |
| Diarrhoea | 3 | 1 | 0.59 | 1 | 0 |
| Dry eyes | 0 | 1 | 0 | 0 | |
| Dry skin | 5 | 4 | 1.00 | 0 | 0 |
| Fatigue | 5 | 2 | 0.36 | 1 | 0 |
| Hypocalcaemia | 1 | 0 | 1 | 0 | |
| Hypomagnesaemia | 1 | 0 | 1 | 0 | |
| Mucositis | 1 | 0 | 1 | 0 | |
| Nail infection | 1 | 6 | 0.06 | 0 | 0 |
| Nausea | 2 | 1 | 1 | 0 | |
| Neutropenia | 1 | 0 | 1 | 0 | |
| Pruritus | 1 | 1 | 0 | 1 | |
| Rash | 6 | 8 | 0.66 | 1 | 0 |
| Renal toxicity | 3 | 0 | 0.21 | 2 | 0 |
| Weight loss | 2 | 0 | 0.48 | 0 | 0 |
CPE: cisplatin-pemetrexed-erlotinib; E: erlotinib. #: due to limited sample size, no statistical analysis was performed for events grade ≥3.